Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis

While typically considered a pulmonary disease, cystic fibrosis patients develop significant nutritional complications and comorbidities, especially those who are pancreatic insufficient. Clinicians must have a high suspicion for cystic fibrosis among patients with clinical symptoms of pancreatic insufficiency, and pancreatic enzymatic replacement therapy (PERT) must be urgently initiated. PERT presents a myriad of considerations for patients and their supporting dieticians and clinicians, including types of administration, therapy failures, and complications.

Automated summary

Cystic fibrosis patients experience significant nutritional complications and comorbidities, especially those with pancreatic insufficiency. Prompt initiation of pancreatic enzymatic replacement therapy (PERT) is crucial and involves considerations such as administration methods, therapy failures, and complications.